GTX Inc.
175 Toyota Plaza
7th Floor
Memphis,
TN 38103
United States - Map
Phone: 901-523-9700
Fax: 901-844-8075
Website: http://www.gtxinc.com
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women primarily through wholesale drug distributors in the United States. It is developing selective androgen receptor modulators (SARMs), including Ostarine (GTx-024), which has completed Phase II clinical trial for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer; and CapesarisTM (GTx-758), a selective estrogen receptor alpha agonist that has completed Phase IIa clinical trial for the first line treatment of advanced prostate cancer. In addition, the company is developing estrogen receptor beta agonists and other novel compounds that are in preclinical development stage for the treatment of metabolic diseases, ophthalmic diseases, cancer, psoriasis, and/or pain. The company was founded in 1997 and is headquartered Memphis, Tennessee. Key Statistics
| |
| GTX Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Low Concern), Compensation (High Concern), Shareholder Rights (High Concern). | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Dr. Mitchell S. Steiner M.D., F.A.C.S,
51
Co-Founder, Vice Chairman and Chief Exec. Officer | 705.00K | 0.00 | Mr. Marc S. Hanover MBA,
49
Co-Founder, Pres and Chief Operating Officer | 600.00K | 0.00 | Mr. Mark E. Mosteller CPA,
49
Chief Financial Officer, Principal Accounting Officer, VP and Treasurer | 355.00K | 0.00 | Dr. James T. Dalton Ph.D.,
49
Chief Scientific Officer and VP | 475.00K | 0.00 | Mr. Henry P. Doggrell ,
63
VP, Gen. Counsel and Sec. | N/A | N/A |
|
| | Amounts are as of Dec 30, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.60% Nasdaq 
0.07(2.33%) May 25, 4:00PM EDT|After Hours:
3.07 0.00 (0.00%) May 25, 4:47PM EDT